Jill Rollet

SAN DIEGO — Genetic evaluation of patients referred to a U.S. glomerular disease center revealed a genetic diagnosis in 35% of cases, informing prognosis and treatment and allowing for family testing, among other benefits.

SAN DIEGO — Among African American and white adults with obesity who received kidneys from the same deceased donor, graft failure rates were

SAN DIEGO — In this video exclusive from ASN Kidney Week, Darcy K. Weidemann, MD, MHS, FAAP, a pediatric nephrologist at Children’s Mercy in Kansas City, Missouri, discusses her top concerns in the specialty: access and workforce.“One of the most exciting developments is in the world of neonatal dialysis,” Weidemann said.

SAN DIEGO — Semaglutide, a GLP-1 receptor agonist approved for treatment of obesity and type 2 diabetes, improved kidney metrics for adults with overweight and obesity without diabetes, according study data.“The FLOW trial demonstrated that semaglutide reduces the risk of a clinical kidney outcome in people with type 2 diabetes and chronic kidney disease. We had also shown previously

Video Player is loading. Play Video Play Mute Current Time Duration Loaded

Video Player is loading. Play Video Play Mute Current Time Duration Loaded

Video Player is loading. Play Video Play Mute Current Time Duration Loaded

Nine months after the ransomware attack on the health payment processing company Change Healthcare, the far-reaching impacts on medical practices, providers and patients continue to be felt.

Long-term albuminuria risks for U.S. adults with Asian/Pacific Islander ancestry who have diabetes and normal kidney function differ across ethnic subgroups, according to data published in Kidney Medicine

Key takeaways: ASN published guidance on managing obesity with kidney disease. Some kidney therapies may promote weight gain, and transplant often requires a weight cap.